Vancomycin-resistant enterococci (VRE) which have been among the important agents of nosocomial infections since 1980 have an upper place among nosocomial pathogens. Penicillin-ampicillin resistance and high-level aminoglycoside resistance which are seen in addition to glycopeptide resistance in enterococci, limit the possibility of therapy. Furthermore, because vancomycin resistance genes can be transferred to Staphylococcus aureus from enterococci in-vitro and nine methicillin-resistant S.aureus strains have been determined up to now in the world, concerns towards VRE has increased. It is highly possible for vancomycin-resistant methicillin-resistant S. aureus (MRSA) strains to spread in countries similar to ours where both MRSA and VRE prevalences are high. The emergence of VRE has raised serious concerns and in response, the Hospital Infections Control Practices Advisory Committee (HICPAC), in collaboration with the Centers for Disease Control and Prevention (CDC), has developed recommendations for preventing the spread of VRE. Specific recommendations were made for surveillance measures to identify patients colonized or infected with VRE, isolation measures to prevent person-to-person transmission of VRE, and rational antibiotic usage.